Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 1, 2016

View Archived Issues

EIB and Transgene enter a financing agreement

Adicet Bio closes Series A financing and acquires Applied Immune Technologies

Epic Sciences and Avera Medical collaborate in personalized cancer medicine trials

RSV Corporation ends RSV collaboration with Mymetics

Shionogi and Nissan Chemical enter strategic antifungal research collaboration agreement

Elotuzumab receives positive CHMP opinion for the treatment of multiple myeloma

VARI-SU2C Epigenetics Dream Team advances trial for metastatic colorectal cancer

Synthetic anion carrier shows activity without toxicity

AbbVie starts enrollment in phase III clinical program for elagolix in uterine fibroids

First patients dosed in phase I trial of ARQ-092 in Proteus syndrome

GenArraytion introduces first commercially available Zika virus test

Cancer drug exhibits promising preclinical results in a DMD model

Allergan enters into a global agreement with AstraZeneca to develop and commercialize ATM-AVI

Celgene reviews activities of fourth quarter 2015

Sareum applies for permission to start clinical trials of Chk1 inhibitor CCT-245737

Amgen reports milestones from fourth quarter 2015

EMA accepts cabozantinib MAA for review

BeiGene reports inhibitors of EGFR T790M mutant

Synergy Pharmaceuticals submits NDA for plecanatide

Pfizer reports muscarinic M1 PAMs

Merck Patent and Cancer Research Technology develop CDK8/19 inhibitors

EMA committee backs approval of Uptravi for PAH

Advenchen Laboratories presents PI3K/mTOR inhibitors

EMA committee recommends approval of Coagadex to treat FX deficiency

FDA gives breakthrough therapy designation to Allergan's rapastinel

Merck & Co. reports ROMK inhibitors

Spectrum Pharmaceuticals begins registrational trial of eflapegrastim

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...